Search

Displaying results 8391 - 8400 of 8547 in total
  1. Drug

    Nitrocefin

    go.drugbank.com/drugs/DB11592
    Experimental

    While other detection methods exist, such as PCR, nitrocefin allows for rapid detection using few materials and inexpensive equipment.

  2. Drug

    Tralesinidase alfa

    go.drugbank.com/drugs/DB17657
    Investigational

    It is being investigated for the treatment of mucopolysaccharidosis type IIIB (MPS IIIB), also known as Sanfilippo syndrome B.[A258828]

  3. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  4. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  5. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  6. Drug

    Tiletamine

    go.drugbank.com/drugs/DB11549
    ExperimentalVet approved

    Tiletamine hydrochloride, the salt form, exists as odorless white crystals.

  7. Drug

    Tanespimycin

    go.drugbank.com/drugs/DB05134
    Investigational

    Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).

  8. Drug

    ABBV-514

    go.drugbank.com/drugs/DB17586
    Investigational

    ABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]

  9. Drug

    D-threo-neopterin

    go.drugbank.com/drugs/DB02385
    Experimental

    (From Stedman, 26th ed) Neopterin also serves as a precursor in the biosynthesis of biopterin.

  10. Drug

    GX-19 Vaccine

    go.drugbank.com/drugs/DB15891
    Investigational

    As of June 2020, the vaccine candidate is undergoing Phase I and Phase IIa trials to determine dose levels for safety and efficacy[A219758,L16488].